Carter Cliff is CEO of Papillon Therapeutics. As co-founder and executive, he has raised $125 million for biotechnology companies developing cell and gene-modified cell therapies, including Opsis Therapeutics, Vascugen, and Ryne-Bio. BlueRock Therapeutics (a Bayer AG company) entered a Strategic R&D Alliance with Opsis, providing Opsis with a $70 million up-front commitment for option of three induced pluripotent stem cell (iPSC) retinal cell therapy programs. Carter previously spearheaded and oversaw development of a portfolio of iPSC therapeutics at FUJIFILM Cellular Dynamics Inc. (FCDI).